GILD

Gilead Sciences, Inc. Press Releases

$105.54
*  
0.40
0.38%
Get GILD Alerts
*Delayed - data as of Jan. 23, 2015  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Morningstar Names John Martin of Gilead Sciences as its 2014 CEO of the Year
1/21/2015 1:06:00 PM - PR Newswire


Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
1/12/2015 5:00:00 PM - Business Wire
▲4.19 % Price Change since this news event. The Volume Ratio is 2.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Prime Therapeutics Breaks from Competition, Strikes Deals to Prefer both Harvoni, Viekira Hepatitis C Drugs
1/12/2015 2:00:00 PM - PR Newswire


Reveal Earnings Forecast for Arena Pharmaceuticals, Petrobras, Alibaba, Apple, Gilead Sciences, and Applied Materials
1/9/2015 8:45:00 AM - PR Newswire


BBCN Bancorp to Announce Fourth Quarter 2014 Financial Results on Monday, January 26, 2015
1/8/2015 5:07:00 PM - GlobeNewswire


PW Partners and HG Vora Nominate Six Highly Qualified Directors to Board of Town Sports
1/7/2015 8:45:00 AM - PR Newswire


Earnings Forecast for Apple, Alibaba, Twitter, Gilead Sciences, Michael Kors, and Tesla
1/7/2015 8:45:00 AM - PR Newswire


Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
1/6/2015 8:30:00 AM - Business Wire
▲7.74 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Reveal Earnings Forecast for Apple, Gilead Sciences, Alibaba, Twitter, BlackBerry, and Sirius XM
1/5/2015 8:45:00 AM - PR Newswire


Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment
12/29/2014 8:30:00 AM - Business Wire


Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment
12/29/2014 8:30:00 AM - Business Wire
▲10.03 % Price Change since this news event. The Volume Ratio is 0.55.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the Treatment of B-cell Malignancies and Other Diseases
12/19/2014 1:00:00 AM - Business Wire
▼-0.37 % Price Change since this news event. The Volume Ratio is 1.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Reveal Earnings Forecast for Apple, Halliburton, American Realty Capital Properties, Gilead Sciences, Zynga, and Bank of America
12/16/2014 8:45:00 AM - PR Newswire


Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics
12/15/2014 8:30:00 AM - Business Wire
▲0.28 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors'' Informational And Educational Use
12/9/2014 4:43:00 PM - PR Newswire
▼-0.26 % Price Change since this news event. The Volume Ratio is 1.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Biogen Idec and Gilead Sciences Join the National Pharmaceutical Council
12/9/2014 9:15:00 AM - PR Newswire


Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma
12/8/2014 10:00:00 AM - Business Wire
▼-1.01 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM
12/8/2014 8:45:00 AM - PR Newswire
▲0.64 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power
12/4/2014 8:45:00 AM - PR Newswire
▲4.89 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo
12/2/2014 8:45:00 AM - PR Newswire


Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries
12/1/2014 7:00:00 AM - PR Newswire


Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry
11/26/2014 8:45:00 AM - PR Newswire


Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba
11/24/2014 8:45:00 AM - PR Newswire


Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power
11/20/2014 8:45:00 AM - PR Newswire


European Commission Grants Marketing Authorization for Gilead’s Harvoni®? (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
11/18/2014 10:07:00 AM - Business Wire